SUMMARY Topical atenolol (a 31-adrenoceptive antagonist), pilocarpine, and placebo were tested in a randomised double-blind crossover trial of 8 patients with ocular hypertension. Atenolol al., 1973). Systemic administration has been reported to reduce the IOP both in healthy volunteers and in patients with increased IOP (Elliot et al., 1975; Wettrell and Pandolfi, 1975; Macdonald et al., 1976 Macdonald et al., , 1977 . It has recently become available for local application. In short-term studies atenolol eye drops have been found to reduce the IOP both in normal eyes and in eyes with elevated IOP .
3 times a day) caused a fall in intraocular pressure (IOP) comparable to that achieved by topical application of pilocarpine (2% 3 times a day). The decrease in IOP by each compound was demonstrable on the second day of application and was significantly (P<005) reduced on the seventh and 14th days of treatment. The combination of 2% pilocarpine and 20% atenolol administered 15 minutes apart (3 times a day) lowered the IOP significantly from the second day of treatment, and this reduction persisted throughout the trial period of 14 days. This combined treatment lowered the IOP more than either substance alone. However, this further decrease was statistically significant only on the 14th day of treatment (atenolol versus atenolol + pilocarpine, P<0.05).
No change of the episcleral venous pressure was observed after 14 days' treatment with either atenolol or pilocarpine alone, or combined.
Atenolol (Tenormin) is a cardioselective (rl)-adrenoceptive antagonist devoid of intrinsic sympathomimetic activity and membrane-stabilising properties (Barret et al., 1973) . Systemic administration has been reported to reduce the IOP both in healthy volunteers and in patients with increased IOP (Elliot et al., 1975; Wettrell and Pandolfi, 1975; Macdonald et al., 1976 Macdonald et al., , 1977 . It has recently become available for local application. In short-term studies atenolol eye drops have been found to reduce the IOP both in normal eyes and in eyes with elevated IOP .
The mechanism by which these drugs exert their effect on the IOP is not yet clear. It may perhaps be by altering the intravascular pressure in the recipient episcleral veins (Prv.) In a recent study (Krakau et al., 1973) .
STATISTICAL ANALYSIS
The mean IOP for all patients during treatment with the various combinations of the drugs were tested statistically with Student's t test for paired data. The recordings made during treatment with placebo and with the active substance were compared. The same procedure was used in the statistical treatment of the Prv. values.
Results

INTRAOCULAR PRESSURE (IOP)
Application of pilocarpine lowered the IOP to roughly the same extent as atenolol (Tables 1, 2, and Fig. 1 ). This decrease was demonstrable on the second day of treatment and was statistically significant (P < 005) from the seventh day and remained so throughout the rest of the treatment period. Although the effect of each drug was still obvious on the 14th day of treatment (Table 2 and Fig. 1) , it was only the recordings at noon that were significantly (P < 005) decreased.
Combined administration of pilocarpine and atenolol significantly lowered the IOP from the second day of treatment and throughout the rest of Fig. 1 ). On the 14th day combined pilocarpine and atenolol caused a statistically significant reduction of IOP throughout the day (P<O005 to P<0-01) ( Table 2 and Fig. 1 ). Combined pilocarpine and atenolol lowered the IOP more than either substance alone, though the difference was not statistically significant with one exception (atenolol compared with atenolol + pilocarpine on the 14th day of treatment).
EPISCLERAL VENOUS PRESSURE
After 14 days' treatment neither pilocarpine nor atenolol separately or combined had any demonstrable effect on the episcleral venous pressure (Table 3) . SIDE 
EFFECTS
One patient reported headache and smarting pain during the initial treatment with pilocarpine. Combined atenolol and pilocarpine caused itching and discomfort of the eyes of 2 patients. However, these disturbances were only moderate and not such as to prevent completion of the trial. Examination In this study topical atenolol (2% 3 times a day)
reduced the IOP to about the same extent as pilocarpine (2 % 3 times a day) in patients with ocular hypertension. This is in agreement with previous reports of the hypotensive effect of topical application of other 3-adrenoceptive inhibitors (Bucci et al., 1968; Vale et al., 1972; Vale and Phillips, 1973; Bonomi and Steindler, 1975; Katz et al., 1976; Bucci, 1976; Krieglstein et al., 1977; Zimmerman and Kaufman, 1977a, b) . The hypotensive effect of topical atenolol has also been demonstrated in healthy volunteers and patients with raised IOP . No reports were available until now on the IOP-decreasing effect of atenolol compared to that of pilocarpine.
The IOP decrease was demonstrable for both drugs on the second day of treatment and was statistically significant from the seventh day of treatment, persisting throughout the rest of the 14-day trial. The decrease in IOP observed during treatment with 2 % atenolol is in fair agreement with that reported by . In that study a larger reduction was observed on the first day of treatment, which, however, gradually diminished to become comparable to the reduction observed in the present investigation. A tendency to tachyphylaxis has also been noted for bupranolol (Krieglstein et al., 1977) .
Although the 2 drugs reduced the IOP to roughly the same extent, they are believed to differ in their mode of action. Thus, pilocarpine is generally believed to facilitate the outflow of aqueous humour (see Gaasterland et al., 1975) , while systemic administration of 5-blocking agents are thought to reduce the production of aqueous humour. A decreased flow has also been suggested to be the main cause of the fall in IOP following topically applied pindolol (Bonomi and Steindler, 1975) . In accordance with a previous investigation of systemic atenolol no influence on the episcleral venous pressure was observed after 14 days' treatment with topical atenolol alone or combined with pilocarpine. This rules out the possibility that alterations in the recipient episcleral veins are responsible for the decrease in IOP. Neither did pilocarpine applied separately for a fortnight have any effect on the episcleral venous pressure, although Wilke (1974) reported an early rise in Prv. after application of 2 % pilocarpine. Combined atenolol and pilocarpine lowered the IOP more than either drug alone. This is in agreement with Bietti's (1972) finding of an additive effect of topical application of propranolol and pilocarpine. The additive effect of combined pilocarpine and atenolol argues against the hypothesis proposed by Phillips et al. (1977) that pilocarpine may reduce the effect of atenolol by causing contraction of the ciliary muscle and thereby prevent the penetration of topical atenolol into the ciliary processes.
According to Macdonald et al. (1976) systemic atenolol is more effective than propranolol in reducing IOP. One might expect this to hold also for topical application of the compounds. This may make topical atenolol (which furthermore lacks anaesthetic properties) more useful in clinical practice.
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